Home
Search results “Chromosome analysis bone marrow”
Conventional Cytogenetics Chromosome Preparation Brief Workflow
 
07:17
Brief Overview of the Workflow
Views: 2167 Kanay Yararbas
What is Karyotyping ?
 
09:57
It is a test to identify size, shape, and number of chromosomes in sample of body cells
Views: 17307 Pathology Simplified
Bone Marrow Smear Preparation
 
03:55
Specimen collection technique for bone marrow samples by Craig E. Litz, M.D. Director, ProPath Hematopathology.
Views: 31014 ProPath Pathology
bone marrow for micronucleus
 
03:20
isolation of femur from wister albino rats and removal of bone marrow cells for micronucleus assessment.
Biggest Discovery Ever Made! Blood of Jesus Tested in Laboratory the Results will Blow your Mind
 
10:02
This discovery will probably never make it to mainstream media world wide, because the discovery was met by strong recistance by higher powers and sadly few people know about this. Therefore, I suggest that you behind the screen, share the clip as freshly as you can to friends and family. Spread the word! JESUS IS ALIVE Ron Wyatt discovered the Ark of the Covenant, and, as a totally unexpected second discovery, to his astonishment found the blood of Christ on its Mercy Seat. A DNA analysis proved the miraculous nature of the blood. Ron Wyatt's discovery should have made international front page news, but was largely blacked out by the corporate news media. It was quietly but excitedly reported on by the Christian news networks. When scientist Richard Rives tested the dried, two-thousand-year-old "dead" blood, he was able to analyze its chromosomes—which is only possible with living blood. Upon further analysis, the blood was found to contain twenty-three chromosomes from the mother (Mary)—as is normal—but only one "Y" chromosome from the Father (God)—which should have been impossible, as regular humans have 23 chromosomes from mother and 23 from the father—a total of 46! Four samples of the literal, physical blood of Jesus Christ have been discovered and tested: one taken from the Shroud of Turin, another obtained from the Veil of Veronica, one from Ron Wyatt's archeological dig beneath the cruxifixction site, and another brought back by the Knights Templar. All four blood-related relics have been associated with numerous miracles and subjected to rigorous scientific testing, the synthesis of scientific and phenomenological evidence, for some, "proof of Jesus". The initial steps towards the scientific study of the Shroud of Turin and the blood of Jesus imbedded in the relic were taken soon after the first set of black and white photographs became available early in the 20th century. In 1902 Yves Delage, a French professor of comparative anatomy, published the first study on the subject. Delage declared the image anatomically flawless and argued that the features of rigor mortis, wounds, and blood flows were evidence that the image was formed by direct or indirect contact with a corpse. William Meacham mentions several other medical studies between 1936 and 1981 that agree with Delage. However, these were all indirect studies without access to the shroud itself. The first direct examination of the shroud by a scientific team was undertaken in 1969–1973 in order to advise on preservation of the shroud and determine specific testing methods. This led to the appointment of an 11-member Turin Commission to advise on the preservation of the relic and on specific testing. Five of the commission members were scientists, and preliminary studies of samples of the fabric were conducted in 1973.
Views: 893852 A & Ω Productions
Tissue Typing
 
07:31
Views: 7728 Brilynn Schrader
Engraftment Monitoring Following Human Stem Cell Transplantation
 
55:19
Chimerism is an extremely rare disorder that mixes the chromosomal population in a single organism. Chimerism may manifest as the presence of two sets of DNA, or organs that do not match the DNA of the rest of the organism. In some cases, hermaphroditic characteristics can be signs of chimerism. Contemporary use of the term chimerism derives from the idea of a mixed entity, referring to someone who has received a transplant of genetically different tissue. Engraftment monitoring, also called chimerism testing, by DNA utilizes methodology commonly used in human identity testing. Dr. Shalini Pereira talks about how this new testing technology identifies genetic profiles of a recipient and donor(s) after a stem cell transplant, and can be used to evaluate the extent of mixture in the recipient's peripheral blood, bone marrow or other tissue. To see more videos from the University of Washington visit uwtv.org.
Views: 2432 UW Video
Ron Wyatt talking about  JESUS blood sample
 
04:28
visit http://users.netconnect.com.au/~leedas/ It will explain where the blood came from. When you get there, hit the 'Ark of the Testament link.' If you want to hear me sing, put atenorforjesus into the youtube search engine. Many people ask when this blood sample will be made public. Our answer to them is that soon there will be in place an international sunday law. All the nations will pass laws requiring their citizens to keep sunday holy. When this law is enforced, 1 the Ten Commandments written by God's finger, 2 the blood sample, 3 clear video of all in the cave will be shown to the human race. When everyone has made their decision either to obey the 7th day Sabbath as written in the 10 Commandments or the Governments sunday law, the 7 last plagues will be poured out on the unprotected heads of those that obey the sunday law and reject God's Sabbath. We would urge you to become acquainted with God's 10 Commandments in Exodus chapter 20 of your King James Bible and have faith in the blood which was poured out for you. Yeshua said that it is impossible for the 10 commandments to be changed. Matt 5:18. If you would like a copy of this DVD email [email protected] For those of you that say that Ron Wyatt never excavated in Jerusalem, see this video. https://www.youtube.com/watch?v=T_l9pUIeBak&t=350s
Views: 448548 atenorforjesus
Chromosomal Microarray Analysis in Pregnancy and Stillbirths
 
34:58
Chromosomal Microarray Analysis in Pregnancy and Stillbirths - Experience from the NICHD Multicenter Prenatal Study and the NICHD SCRN Study Brynn Levy, MSc, PhD, Director, Clinical Cytogenetics Laboratory, Associate Professor of Clinical Pathology, College of Physicians and Surgeons of Columbia University, USA Проф. Бринн Леви, директор крупной цитогенетической лаборатории, рассказывает о применении микроматричных технологий в пренатальной диагностике и сравнивает метод с кариотипированием, ультразвуковой диагностикой и другими методами по эффективности. Профессор рассказал о крупнейшем исследовании, проведенном с использованием метода кариотипирования и микроматричных технологий, в котором приняли участие 4450 пациентов. Описаны аномалии генома, которые были выявлены платформой Affymetrix, но не были детектированы кариотипированием. Микроматрицы также позволили предсказать некоторые дефекты плода, возникшие у него впоследствии. По результатам проделанной работы, исследователи рекомендуют микроматрицы в качестве основного диагностического метода в пренатальном скрининге. Также, лабораторией было проведено сравнение диагностической эффективности традиционного кариотипирования с микроматрицами в скрининге мертворожденных. Последний метод показал на 41.7% больший процент детектируемых полиморфизмов и более высокую диагностическую эффективность.
Views: 146 Геномед
Harvesting thru Analysis The New Cytogenetics Workflow - ADS Biotec
 
03:43
Harvesting thru Analysis The New Cytogenetics Workflow
Views: 126 ADS Biotec Omaha
FFPE FISH Protocol
 
10:23
Our pretreatment kit is capable of preparing slides for CISH and/or FISH analysis on formalin-fixed, paraffin-embedded (FFPE) tissue. Watch our video showing step-by-step instructions on how to use the kit with our extensive Aquarius® Pathology FISH probe range.
4 hour FISH Workflow for FFPE, Blood, and Bone Marrow Specimens
 
18:16
ProPath Comparison between Agilent probes and DAKO Histology Kit Agilent provides a comprehensive menu of FISH probes for rapid identification of a wide range of chromosomal aberrations across the genome. SureFISH's unique design methodology for specific targets provides excellent resolution with high sensitivity and specificity: Unique Design Methodology Agilent's Comprehensive Menu of FISH Probes Provides: Coverage of the Most Relevant Targets Broad Menu: Hundreds of relevant probes Excellent Performance High resolution compared to BACs High sensitivity and specificity Probes designed to meet ACMG guidelines for clinical cytogenetics Flexibility Probes offered in the following colors: Green( ex: 495nm; em:517nm) Red( ex:547nm; em: 565nm) Blue ( ex: 429nm; em: 470nm) Unique in silico design methodology for targeting specific regions Pre-labeled probes to reduce labor time Compatible with established FISH procedures and filter sets Quality Control Probe localization to correct chromosome, demonstrated by hybridization images for every probe Integration with Agilent CytoGenomics Data Analysis Software Visualizing the probe of interest in Agilent CytoGenomics software Link from CytoGenomics software to the SureFISH website for streamlined order process Regulatory Compliant SureFish probes are Analyte Specific Reagents. Analytical and performance characteristics are not established. SureFish probes are produced in an ISO 13485-certified facility that is registered with the FDA as a medical device manufacturing establishment. http://www.genomics.agilent.com/surefishArticle.jsp?pageId=3004&_requestid=797254 http://www.genomics.agilent.com/surefish-home.jsp?&_requestid=797450 http://www.dako.com/dist/propath-her2-iqfish-whitepaper_29087.pdf http://www.dako.com/dist/index/products/featured-solutions/her2-iqfish-pharmdx.htm#tab3
Views: 419 Life Trade - Egypt
Standard Agilent FISH Protocol: Blood and Bone Marrow
 
07:35
Video describes processing and hybridization of blood and bone marrow samples using Agilent reagents. Learn more at http://www.genomics.agilent.com/surefish-home.jsp
9 Warning Signs of Bone Marrow Cancer
 
09:56
9 Warning Signs of bonee Marrow Cancer: 1. Exhaustion One of the earliest signs of multiple myeloma is a general feeling of exhaustion that fails to go away, even when one gets lots of rest and follows a healthy diet. These feelings of fatigue are usually related to the way multiple myeloma attacks the healthy cells of the bonee marrow, which in many cases can result in anemia or inconsistent cytokine production. Because feelings of fatigue are fairly common, this symptom should be considered in combination with other signs of multiple myeloma on this list. For example, someone who has a family history of cancer, and especially bonee marrow cancer, will want to be tested for multiple myeloma if they suddenly experience a long, generally unbreaking wave of exhaustion lasting several days or weeks. 2. Anemia Anemia, which occurs when the number of red blood cells reaches critically low levels, results from multiple myeloma because it causes the suppression or crowding out of healthy red blood cells. The most common side effect of anemia is an overpowering feeling of fatigue that may not break even with healthy diet, ample rest, fluids, or stimulants like caffeine. This feeling of general exhaustion can last for days or even weeks at a time. However, it should be noted that anemia is not only related to multiple myeloma and the development of bonee marrow cancer. It can result from a number of other health conditions, from pregnancy to menstruationn and iron and vitamin deficiency. Simply failing to get enough iron in the diet can cause anemia. 3. Pain in the bonees One of the more obvious and distinct signs of multiple myeloma is feelings of pain in the bonees. This is because multiple myeloma forms in the marrow of the bonee and, as time goes on, its suppression of healthy red blood cells can cause the bonee to thin and weaken, resulting in osteoporosis. Once this stage is reached, the chance of fracturing or completely breaking the affected bonee increases substantially. It also results in mild to moderate feelings of pain in and around the bonee. This pain may be more noticeable if the problem involves particularly critical bonees, such as the spine, which are responsible for supporting multiple parts of the body. This pain tends to increase with movement and may be considerably more noticeable during the evening and early morning hours. If the spine is affected, the patient may experience compression fractures that cause slumping; over time, this could even result in a patient losing a few inches from their height. 4. Numbness Because multiple myeloma targets the healthy red blood cells of the bonee marrow, in time it can cause the patient’s bonees to weaken. While this often results in the affected bonees becoming frailer and painful, it can also lead to general feelings of numbness. This sensation of numbness is most pronounced when multiple myeloma invades the vertebrae of the spine. As the problem spreads through the spine, it causes the bonees to weaken, resulting in vertebrae coming into contact with each other and the nerves spiraling around the spine. In touching upon these highly sensitive nerves, multiple myeloma effectively scrambles the signal traveling between the brain and spine, leaving the area feeling numb. 5. Kidney problems If not caught early on, multiple myeloma can eventually lead to significant problems in the kidney. This is because the development of multiple myeloma results in the emergence of proteins that, when produced to excess — as they often are when multiple myeloma takes hold — can put undue pressure on the kidneys, resulting in damage or even kidney failure. Ideally, the patient would recognize other signs and symptoms of multiple myeloma — such as excessive fatigue or bonee pain — and be able to take action prior to reaching the stage where kidney problems emerge. However, should those signs not raise flags, the emergence of kidney-related issues should be identified as a possible sign of multiple myeloma. 6. Hypercalcemia Over time, multiple myeloma results in the production of cancerous cells that effectively push healthy cells out of the bonee marrow. This makes the bonee feel weak, painful, and potentially numb. In time, it could cause the bonee to fracture or completely break. This wearing down of the bonees through multiple myeloma also results in a condition known as hypercalcemia, which emerges when there is an excessive amount of calcium in the blood. Hypercalcemia is often found in people with multiple myeloma, because their bonees, which contain calcium, are effectively breaking down. Hypercalcemia introduces its own, rather significant health problems, from exhaustion to constipation and kidney issues. 7. Weight loss 8. Mental confusion 9. Frequent illnesses
Views: 34168 HEALTH AREA
Acute Myelogenous Leukemia (AML) & Chronic Myelogenous Leukemia (CML)for USMLE
 
27:18
Handwritten video lecture on Acute Myelogenous Leukemia (AML) and Chronic Myelogenous Leukemia (CML) for the USMLE. Will discuss Pathophysiology, Signs and Symptoms, Treatment and Prognosis Pathophysiology of Myelogenous Leukemia The stem cells are found in the bone marrow which gives rise to myeloid stem cells which then give rise to myelobast and then the granulocytes (Eosinophils, Basophils, Neutrophils) In Acute Myelogenous Luekemia there is an increase in Myeloblasts and may even involve myeloid stem cell which will affect red blood cells and platelets. In Chronic Myelogenous Leukemia there is an increase in Tyrosine Kinase which increases the number of the granulocytes that are found. ACUTE MYELOGENOUS LUEKEMIA Arrests at precursor stage with more than 20percent blasts in Bone Marrow. Blasts accumulate in bone marrow and goes to peripheral tissue. Common to have decreased Red Blood Cells and Platelets as Bone marrow gets crowded. Changes in Growth Factor causes arrest of development or decreased apoptosis. Myelodysplastic syndrome is a minor change in stem cells that is not cancerous yet, but it commonly develops into cancer. CLASSIFICATION – Currently classification is adopted by WHO which is based on therapeutic targets. 1. AML wiith recurrent abnormalities a. 8 21 translocation, b. t(15 17) Promyelocytic Leukemia i. Auer rods (M3). ii. PML RaR translocation (may be treated with retinoic acid) 2. AML with Myelodysplastic Syndrome (Poor Prognosis) 3. AML that is therapy related – due to cytotoxic agents 4. AML, not specified – classified from M0 to M7 CLINICAL - Sudden onset also may have thrombocytopenia, anemia, bone main and may affect liver, spleen, lymph node. After treatment patient may experience tumor lysis syndrome (high K, High Uric acid, High Phosphate, Low Calcium) INVESTIGATIONS – Usually show normocytic anemia and thrombocytopenia. Blood smear shows blasts which are myeloperoxidase positive. Bone marrow aspiration will show hypercellular with more than 20 percent blasts. Cytogenetic analysis help with prognosis. TREATMENT – Induction consists of 7 days of IV cytarabine with 3 days of short acting anthracycline to kills as much of blasts as possible. Consolidation to mop up left over with high dose cytarabine. If remission favorable and young age then continue more cycles of cytarabine. If no resmission or comorbidities than perform stem cell transplant and investigation therapies. PROGNOSIS – depends on age. As age increases the prognosis is worse CHRONIC MYELOGENOUS LUEKEMIA PATHOGENESIS – Translocation between chromosome 9 (ABL1) and Chromosome 22 (BCL). ABL is responsible for production of tyrosine kinase which is tightly regulated. ABL transfers over to BCL on chromosome 22 known as ABL BCR fusion and the Philadelphia chromosome. This leads to constant production of tyrosine kinase. CLINICAL – has more insidious onset and found as incidental finding. Chronic phase is symptomatic but can be controlled with treatment. Accelerated phase there is an increase in the number of blasts and will be less responsive to treatment. Final stage is blast crisis is when it transforms to AML with extramedullary syndromes. INVESTIGATIONS – High level of leukocytosis that are LAP negative to rule out leukemoid reaction. Cytogenetic analysis is diagnostic. Flow cytometry identifies CD Markers present. TREATMENT – In chronic phase give imatinib meyslete which is a tyrosine kinase inhibitor, but this is not a cure and the disease is always there. Accelerated blast crisis then look for hematopoietic stem cell transplant which is curative. Interferon alpha and Busulfan can be used while waiting for donor.
Views: 15664 the study spot
Life after bone marrow transplant - Julija Sipavicius
 
45:49
The more common potential short and long term complications associated with transplant; post-transplant clinical recommendations for screening and preventative practices; and some practical tips for life after transplant. The 2017 Blood Cancer Patient Forum was hosted in Auckland, New Zealand on Saturday 9 September by Leukaemia & Blood Cancer New Zealand. ABOUT THE SPEAKER Julija Sipavicius is a registered nurse with over 20 years’ experience in the field of haematology and blood and marrow transplant (BMT) nursing. Julija currently works as the Haematology/BMT Nurse Practitioner at the Royal North Shore Hospital in Sydney. Her core clinical work is in BMT with a focus on post-transplant care and long term follow-up, in addition to managing patients with multiple myeloma.
Hanabi PVI Metaphase Spreader - ADS Biotec
 
02:41
The HANABI PVI Metaphase Spreader has been designed to provide optimized environmental conditions for metaphase chromosome spread preparations. Temperature, humidity and airflow are set and rapidly stabilized so when chromosomes are dropped and spread on microscope slides, they are dried in a consistent and reproducible manner. Excessive spreading and chromosome overlaps are minimized, giving rise to better yields of analysable metaphases. The chromosome spreading process for conventional G-banding (or equivalent) and FISH analysis of samples derived from blood cells or bone marrow samples, is now more streamlined and can easily be carried out regardless of skill level. Protocols requiring cells and chromosomes are spread on the entire slide can be achieved using the tilted slide. Please visit http://www.adsbiotec.com/product/hanabi-pvi-metaphase-spreader/ for more information.
Views: 360 ADS Biotec Omaha
Chronic Myeloid Leukemia Understanding Your Diagnosis
 
04:26
Unending Myeloid Leukemia Understanding Your Diagnosis. In the event that you've been as of late determined to have ceaseless myeloid leukemia, you presumably have a considerable measure of inquiries. Get some answers concerning this kind of tumor, including how it begins and its causes. Endless myeloid leukemia is now and then called ceaseless myelogenous leukemia, or just CML. Leukemia is a sort of growth that starts in the blood-framing cells inside the bone marrow before spreading through the blood. Understanding Bone Marrow: Bone marrow is a delicate substance found inside the bones in the body. It's comprised of a few kinds of cells, including blood undeveloped cells. These cells form into every one of the cells that make up blood, for example, white platelets, red platelets, and platelets. Some white platelets are called lymphocytes, and work to battle disease. The other platelets, including staying white cells, red cells, and platelets, are called myeloids. Endless Myeloid Leukemia: What Is It?. CML is alluded to as "endless" on the grounds that it is a long haul issue in which the destructive cells develop over an expanded timeframe. The cells are permitted to halfway grow, however don't completely develop. The "myeloid" grouping originates from the kind of cells influenced. There are three periods of CML: interminable, quickened, and impact emergency. The vast majority are generally analyzed amid the principal stage when cells are developing gradually. Amid the quickened stage, the sick cells start developing all the more rapidly. On the off chance that left untreated, CML may advance into the impact emergency stage. This is the point at which the bone marrow falls flat and genuine draining and disease can create. Manifestations of CML. Manifestations have a tendency to grow step by step. They can shift contingent upon which period of CML you're in, yet frequently include: *fatigue, in all likelihood because of weakness. *rash. *bruising or draining effortlessly. *bone and joint agony. *enlarged spleen. *increased danger of contamination. How Can It Start?. CML gives off an impression of being for the most part hereditary. A great many people who are analyzed have an unusual chromosome called the Philadelphia chromosome that makes another quality. This quality advises the platelets to make excessively of the tyrosine kinase protein. This enables the infected platelets to replicate too rapidly and live too long. As these cells develop, they don't leave enough space for solid platelets. This procedure can take quite a while. Some of the time individuals don't know they have CML until the point that years after the malignancy cells started to create. What Are the Causes and Risk Factors?. Despite the fact that CML is typically connected with a quality transformation, take note of that it's not innate. It's trusted that the quality change occurs sooner or later after the individual is conceived. While it's as yet not clear precisely how or why this change happens, some hazard factors include: *male sexual orientation. *older age. *exposure to radiation, including a few kinds of tumor radiation treatment. A great many people with CML are treated with drugs called tyrosine kinase inhibitors, or TKIs. These are pills that objective the protein made by the Philadelphia chromosome. Now and again, oral chemotherapy drugs are likewise used to lessen the quantity of strange white platelets. These medications, alone or in blend, are frequently enough to put the leukemia into abatement. Different methodology can likewise be considered, including undifferentiated cell transplants or bone marrow transplants. All Photos Licensed Under CC Source : www.pexels.com www.pixabay.com www.commons.wikimedia.org
Views: 2238 Natural Step
Understanding Bone Marrow Transplantation - from the Clinical and Personal Perspectives
 
57:53
A bone marrow transplant is a multi-step procedure to replace damaged or destroyed bone marrow with healthy bone marrow stem cells, and it is used to treat certain blood cancers like lymphoma and leukemia, as well as aplastic anemia and other immune and genetic diseases. This talk discussed current treatment regimens. It also addressed the complexities that can be overwhelming for the family, as well as the patient, of going through bone marrow transplantation. Speakers: David Miklos, MD Bonnie Willdorf, author of Dancing with Cancer – Maladies and Miracles in Stem Cell Transplantation
Karyotyping
 
07:50
Views: 155 Aizaz Chaudhary
Soft Tissue Found Inside a Dinosaur Bone!
 
08:09
In 2003, an exceptionally well preserved T. rex leg bone was unearthed in the Cretaceous rocks of Montana. Upon close examination, Dr. Mary Schweitzer found the bone to contain soft tissue inside - tiny blood vessels and proteins! Some claim that this is evidence of a young Earth, a recent extinction of the dinosaurs. Could this be, or is there another explanation? ============= Update: since writing the script for this video, a new study came out that weakens the consensus that the tissue found belongs to the original T. rex: http://rspb.royalsocietypublishing.org/content/284/1855/20170544 ============= ======== Support us on Patreon: https://www.patreon.com/statedclearly Get a T. rex t-shirt: https://www.redbubble.com/people/statedclearly/works/28105774-gloating-t-rex?asc=t&p=t-shirt Visit Dr. Mary Schweitzer’s website: https://molecularpaleo.wordpress.ncsu.edu/ ======== Papers cited in this animation: ORIGINAL DISCOVERY OF SOFT TISSUE: Soft Tissue Vessels and Cellular Preservation in Tyrannosaurus rex: http://science.sciencemag.org/content/307/5717/1952 Soft tissue and cellular preservation in vertebrate skeletal elements from the Cretaceous to the present: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1685849/ CRITIQUE OF DISCOVERY: Dinosaurian Soft Tissues Interpreted as Bacterial Biofilms: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2483347/ DEFENSES OF DISCOVERY: Influence of Microbial Biofilms on the Preservation of Primary Soft Tissue in Fossil and Extant Archosaurs: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2953520/ Molecular analyses of dinosaur osteocytes support the presence of endogenous molecules: http://www.thebonejournal.com/article/S8756-3282(12)01318-X/fulltext Testing the Hypothesis of Biofilm as a Source for Soft Tissue and Cell-Like Structures Preserved in Dinosaur Bone: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4771714/ 10 million year old frog bones with marrow preserved: https://pubs.geoscienceworld.org/geology/article-abstract/34/8/641/129601/high-fidelity-organic-preservation-of-bone-marrow?redirectedFrom=fulltext IRON’S ROLE IN PRESERVATION: A role for iron and oxygen chemistry in preserving soft tissues, cells and molecules from deep time: http://rspb.royalsocietypublishing.org/content/281/1775/20132741 OTHER DINOSAURS WITH SOFT TISSUE DISCOVERED: Mass Spectrometry and Antibody-Based Characterization of Blood Vessels from Brachylophosaurus canadensis: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4768904/ Evidence of preserved collagen in an Early Jurassic sauropodomorph dinosaur revealed by synchrotron FTIR microspectroscopy: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5290320/ Soft sheets of fibrillar bone from a fossil of the supraorbital horn of the dinosaur Triceratops horridus: https://www.ncbi.nlm.nih.gov/pubmed/23414624 Hemoglobin-derived porphyrins preserved in a Middle Eocene blood-engorged mosquito: https://www.ncbi.nlm.nih.gov/pubmed/24127577 Molecular preservation in Late Cretaceous sauropod dinosaur eggshells https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1599869/
Views: 57602 Stated Clearly
The Great Search - HLA Typing, Donor Selection and Beyond
 
32:31
2015 Clinical Education Conference Lisa Getzendaner, PA-C, MHS, Fred Hutchinson Cancer Research Center
Views: 21274 ASBMT
Dr. Erba Describes Proper Diagnostic Testing of CML
 
02:39
Harry Erba, MD, PhD, associate professor, Department of Internal Medicine, University of Michigan Health System, discusses the full histopathological examination that should be performed when a patient is diagnosed with chronic myeloid leukemia (CML). If the routine complete blood count shows leukocytosis, a shift in maturity, basophilia, and splenomegaly, 98 times out of 100 the patients will have CML, possibly in the chronic phase. This holds true whether constitutional symptoms are present or not. There are ways to make a non-invasive diagnosis for CML using fluorescence in situ hybridization (FISH) or polymerase chain reaction (PCR) on the peripheral blood to check for a BCR-ABL gene rearrangement. However, Erba does not recommend using this method, stating that CML requires a more thorough baseline analysis. Bone marrow biopsy is critical at the time of diagnosis to provide morphologic evidence of the phase. The biopsy can show fibrosis or the clustering of mature cells indicating whether the cancer is in chronic, accelerated, or blast phase. Knowing the phase of the disease will help choose an appropriate therapy. A cytogenetic analysis of the chromosomes at metaphase, the most condensed and easiest to distinguish phase in the cell cycle, may demonstrate clonal evolution or other changes that could upgrade the patient to a higher phase. The analysis may also show that some patients are not Philadelphia chromosome positive at metaphase, making it less likely to mistake a negative test later as a complete cytogenetic remission. Additionally Erba recommends the completion of a FISH analysis at the time of diagnosis. Approximately 10% of patients have a variant FISH pattern, which is important to know early on. The final test that Erba recommends is a reverse transcription (RT)-PCR. The results of this test can be used as a baseline for response and to verify that the primers used in most commercial laboratories for detecting the BCR-ABL transcription are applicable. Some patients demonstrate variant break points, which makes it easier to arrive at the wrong conclusions if the RT-PCR test is not completed.
Views: 1015 OncLiveTV
Cytogenetics. Human chromosomes. Karyotype.
 
04:50
A chromosome is an organized structure of DNA and protein that is found in cells. It is a single piece of coiled DNA containing many genes, regulatory elements and other nucleotide sequences. ... http://en.wikipedia.org/wiki/Chromosome http://en.wikipedia.org/wiki/Cytogenetics http://en.wikipedia.org/wiki/Karyotype
Views: 61067 microveda
What are the practical details of FISH testing?
 
04:01
In this week's video, Dr. Brian Durie discusses the practical details of Flourescent In Situ Hybridization (FISH) testing. Please subscribe to our channel! Subscribe to International Myeloma Foundation: http://bit.ly/XlUtPE Visit our website at: http://www.myeloma.org Find us online: Facebook: http://facebook.com/myeloma Google+: http://gplus.to/imfmyeloma IMF on twitter: @IMFMyeloma (http://twitter.com/imfmyeloma) Dr. Durie on twitter: @BrianDurieMD (http://twitter.com/brianduriemd) Support the IMF! http://bit.ly/WskQHC Category Nonprofits & Activism License Standard YouTube License
4) Dr.Gihan [Cytogenetics] 16/11/2013
 
02:15:52
Cytogenetics : - The cell cycle - Cell division - Human chromosome
Molecular Cytogenetics FISH and Array Workflow
 
05:58
A brief demonstration from the lab,
Views: 286 Kanay Yararbas
Phases of Chronic Myeloid Leukemia
 
04:34
Periods of Chronic Myeloid Leukemia. What is unending myeloid leukemia?. Interminable myeloid leukemia, or CML, is one of four sorts of malignancy that starts in the bone marrow. It begins in the blood-framing cells and can inevitably spread all through the body by means of the blood. Since CML is a ceaseless type of tumor, it goes ahead bit by bit and goes on for a considerable length of time. This varies from intense kinds of leukemia, which start abruptly and are quickly dangerous. CML is caused by a hereditary transformation that outcomes in platelets creating excessively of the tyrosine kinase protein. This protein causes an overproduction of sick platelets, and enables them to live too long. In the long run, these ailing cells rule out solid platelets. Periods of CML: There are three periods of CML: endless, quickened, and blastic. The stage is controlled by the movement of the malady and is estimated by the quantity of impact cells. Impact cells are unusual white platelets that don't develop appropriately and swarm out solid cells. Endless: The primary period of CML is the perpetual stage. The vast majority are determined to have CML amid this stage. Amid the endless stage, disease cells develop and increase gradually. This stage can last inconclusively and indications are exceptionally mellow or not present by any means. Those with CML may not know they have the illness for quite a long while. A finding for the most part comes about because of blood tests given for an inconsequential reason. Quickened: A moderately modest number of individuals will advance from the ceaseless stage to the quickened stage. In the quickened stage, the impact cells develop and duplicate all the more rapidly, and they appear to quit reacting to treatment. Individuals in this stage may see manifestations like weariness, caused by a lower number of red platelets, and stomach torment because of a broadened spleen. Different highlights of this stage incorporate a low platelet tally and strangely high or low quantities of white platelets. Blastic: On the off chance that left untreated, those with CML can advance to the third stage. In the blastic stage, the impact cells have achieved a basic level. These levels are here and there equivalent to those found in individuals with intense leukemia. This surge of impact cells prompts perilously low levels of red platelets and platelets. Indications are more extreme, and can include: *rash. *bruising and draining effortlessly. *bone and joint agony. *stomach torment. *more articulated weariness. *difficulty relaxing. *increased danger of contamination. *night sweats. *weight misfortune. Amid the blastic stage, CML is hard to treat and is thought to be dangerous. Treatment alternatives: At the point when analyzed in the ceaseless stage, CML is generally first treated with drugs called tyrosine kinase inhibitors, or TKIs. TKIs are meds that objective the protein created by the harmful cells. This sort of treatment is regularly enough to place CML into abatement. At times, oral chemotherapy is likewise used to kill off some white platelets, if white cell levels have turned out to be too high. Despite the fact that these medications can't totally cure CML, individuals typically react great and stay going away for a long time. More forceful treatment choices must be considered for those in the quickened stage. Undifferentiated cell transplants or bone marrow transplants are the following course of treatment, and can bring about a genuine cure. Transplants are additionally prescribed for the individuals who have advanced to the blastic stage. Treatment is considerably more troublesome amid this stage in light of the fact that there are less solid cells. Remaining solid: It's imperative to take after your specialist's prescribed course of treatment when you're determined to have CML. Holding up until the point that you have repulsive side effects or until the point when you have come to the quickened or blastic stage can make your CML considerably harder to treat. Myeloid Leukemia,Chronic Myeloid Leukemia,what is leukemia,Phases of Chronic Myeloid Leukemia,What is unending myeloid leukemia?,what is chronic myeloid leukemia,acute myeloid leukemia,leukemia,chronic myeloid,myeloproliferative disorders,chronic myeloid leukemia treatment,chronic myeloid leukemia causes,symptoms of leukemia,leukemia symptoms,acute leukemia,chronic myeloid leukemia symptoms,leukemia rash,signs of leukemia,what causes leukemia,cancer All Photos Licensed Under CC Source : www.pexels.com www.pixabay.com www.commons.wikimedia.org
Views: 3280 5 Minute Remedies
Engraftment Monitoring Following Human Stem Cell Transplantation - Shalini Pereira, Ph.D.
 
55:13
Chimerism is an extremely rare disorder that mixes the chromosomal population in a single organism. Chimerism may manifest as the presence of two sets of DNA, or organs that do not match the DNA of the rest of the organism. In some cases, hermaphroditic characteristics can be signs of chimerism. Contemporary use of the term chimerism derives from the idea of a "mixed" entity, referring to someone who has received a transplant of genetically different tissue. Engraftment monitoring, also called chimerism testing, by DNA utilizes methodology commonly used in human identity testing. Dr. Shalini Pereira talks about how this new testing technology identifies genetic profiles of a recipient and donor(s) after a stem cell transplant, and can be used to evaluate the extent of mixture in the recipient's peripheral blood, bone marrow or other tissue. Shalini Pereira, Ph.D.
Views: 462 UW Video
What Is In EPO?
 
00:45
I installed on its 300 pcs. Erythropoietin promotes the formation of red blood cells by bone marrow. It's commonly used to treat anemia, often due kidney disease or cancer jan 28, 2006 bbc sport online examines epo, erythropoietin, the latest performance enhancing drug hit athletics. Epo)? Test, definition, side effectsbbc sport erythropoietin wikipediarunner's world. Introduction to mcafee epolicy orchestrator the effect of epo on performance ten things you need know about lagos, nigeria anemia drug made by chemists, not cells mit technology what is agent? What epo? Webopedia definitionmcafee (epo) dell. I've never used mcafee before and have been told. Epo)? Test, definition, side effects erythropoietin (epo) is a hormone produced by the kidney. The mcafee security risk management strategy enables intelligent and compliance optimization, delivered by an epo, or exclusive provider organization, is a type of health insurance plan that offers local network doctors hospitals for you to choose from, identifying candidates erythropoietin (epo) replacement therapy (eg, chronic renal failure). What is epo insurance and how does it work? Epo clinical erythropoietin (epo), serumepo guide for institutions help & support. Evaluating patients undergoing epo replacement therapy who the european patent office (epo) has been granting software patents in europe despite law (as per epc) explicitly forbidding it. It binds with receptors in your bone marrow and cranks up red blood cell count. Epo is a protein hormone nov 7, 2007 scientific comment and analysis of sports sporting performance apr 23, 2014 whether you're new to epolicy orchestrator (epo) or seasoned pro, you may not know all the ins outs this security management dec 13, 2013 erythropoietin, epo, boosts production red blood cells used treat anemia, which often caused by cancer, chemotherapy, mar 31, 2015 epo stands for orchestrator, an integrated software program designed integrate numerous programs short emergency power off; Also referred as switch what obligations do administrators have vis epo? Can revoke their own administrator rights? Is my company obliged mcafee. Erythropoietin can be synthesized and used as a treatment of some forms anemia may 20, 2011 that stimulates red blood cell production epo regulates how many cells your body produces. Solved] how do i find where mcafee epo is installed? Spiceworks. The erythropoietin hormone level can be detected and measured in the blood (the epo test). The profit motive you need to prepare your systems allow epo connect and configure computers traffic return through any institutional border firewall or i've just started working at a site which has mcafee virusscan 8. What is it? Erythropoietin (epo) a erythropoietin (epo), also known as hematopoietin or hemopoietin, glycoprotein cytokine secreted by the kidney in response to hypoxia that stimulates red aug 21, 2014 simple picture epo production of blood cells, which improves delivery oxygen from lun
Views: 130 Bet 2 Bet
The issue of relapse in Philadelphia chromosome-positive ALL patients and how to combat this
 
01:52
Philippe Rousselot, MD, PhD from Versailles Hospital and University, Versailles, France discusses the current medical need of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) patients. After five years of follow up, most studies have shown a relapse rate of around 60%, despite the combination of tyrosine kinase inhibitors (TKI’s, mainly imatinib and chemotherapy), with various dosage levels, as well as the aim of allogeneic bone marrow transplantation. Prof. Rousselot, goes on to discuss a trial (NCT00391989) testing dasatinib as first-line treatment in elderly ALL patients. Very few of the participants had been allografted and of those that relapsed, analysis showed an association with the T315I mutation. The T315I mutation is able to be detected before relapse and at diagnosis, making it possible to better characterize these patients. Prof. Rousselot ends the interview by mentioning a new approach to combating relapse, monoclonal antibodies. These were evaluated in relapsed/refractory patients, and are now on the way to being introduced in the frontline setting. He believes the possibility to combine a monoclonal antibody with a TKI will be available within one year. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
HANABI HARVESTER PII - One Protocol_Different samples sources - ADS Biotec
 
02:51
Blood and Bone Marrow samples in one run.
Views: 240 ADS Biotec Omaha
From Stem Cells To Cancer Cells
 
58:57
Fernando Camargo discusses his research on how cancer arises, what can be done to stop it, and whether cancer is related to stem cells. The human stem cells found in our bone marrow have the amazing ability to develop into different types of cells such as blood or immune system cells. This happens in all of us everyday, but we know little about how it happens. Camargo's research centers on figuring out how stem cells travel down their path to become a new bone or blood cell. Recently, new theories suggest that stem cells have some of the same characteristics as cancer cells. Figuring out how stem cells replicate themselves, divide into specialized cells, or even give rise to a cancer would provide answers for research scientists and maybe treatments for patients.
Views: 349 WGBHForum
Introducing the HANABI Harvesters - ADS Biotec
 
07:08
The HANABI Metaphase Chromosome Harvesters are the first systems to fully automate the multi-step process of preparing and harvesting metaphase cells derived from blood and bone marrow cell cultures and from other cell suspension cultures for cytogenetic analyses. Centrifugation, aspiration, addition of hypotonic and fixative solutions, and cell resuspension are all automated. Walk away reliability and low maintenance significantly reduce FTE time associated with the manual harvesting process. Please visit http://www.adsbiotec.com/product/chromosome-harvesting/ for more information.
Views: 501 ADS Biotec Omaha
Molecular Video Lecture 01:  Variants, Nomenclature, Nucleic Acid
 
58:52
Topics: * Germline vs somatic testing 1:14 * Analytical sensitivity in germline testing 4:40 * Analytical sensitivity in somatic testing 6:34 * Sanger sequencing limit of detection 10:20 * Important of preanalytic assessment of tumor cellularity 10:39 * Different types of variants/mutations 12:57 * Single nucleotide variants or polymorphisms/point mutations 13:39 * SNV/point mutation consequences 14:46 * Nonsense variants 15:09 * Missense variants 15:33 * Synonymous variants 15:54 * Nonsynonymous variants 16:26 * Indel variants 17:00 * Frameshift variants 17:20 * Copy number variants 18:14 * Rearrangements 19:25 * Translocations, balanced vs unbalanced 20:45 * Inversions, peri- vs para-centric 21:08 * Epigenetic changes 22:38 * Methylation 22:50 * Histone modification 23:25 * Nomenclature 24:27 * HGNC 25:30 * HGVS 26:39 * HGVS for SNVs (DNA) 27:03 * HGVS for splice/intronic variant (DNA) 32:19 * HGVS for indels (DNA) 34:14 * HGVS for SNVs (protein) 36:37 * Nucleic acid extraction 39:10 * Intracellular biochemical substrates 39:25 * Preanalytical circling of tumor on H&E 42:06 * Coring vs. scraping 43:00 * Blood/bone marrow specimens 46:32 * Formalin fixed paraffin embedded (FFPE) tissue 46:52 * Cell lysis 47:51 * Nucleic acid isolation 51:50 * Isolation by silica membrane column 52:10 * Phenol/cholorform extraction/alcohol precipitation 53:35 * SPRI bead based isolation 56:10 * Ultracentrifugation 58:06
Views: 1342 long le
The Conspiracy to Hide the Blood of Jesus Christ
 
09:50
There is a conspiracy to hide the physical blood of Jesus. And it is very real. His DNA is scientific proof that Jesus not only walked the earth, but was the biological Son of God. In this clip of an interview from the documentary film Revealing God's Treasure (1998), Ron Wyatt exposes false claims by the Israeli Department of Antiquities, and why they know that both the blood of Jesus—and the Ark of the Covenant—have been found, and reasons why the Israeli authorities do not want Israel—or the world—to ever find out about this discovery, which is scientific proof of both the existence of the historical Jesus and His divinity. Ron tells of how he had applied for and received a permit, and was licensed by four men from the Israeli Department of Antiquity to dig and excavate in Israel. Ron also exposes the corruption of the Israeli government by offering proof of their lies, showing the media photographs of him taken with one of the multiple heads of the Antiquities Department that Ron had met with—who had previously denied ever having met with Ron after the authorities had confiscated remaining artifacts and analyses and apparently classified the discoveries as Top Secret. Ron says, "What I was told by the men I worked with—and if you have a photographic memory you'll remember their names [he jokes]—Amos Kloner, Joseph Gat, Dan Bahat, General Drori. These men have asked me not to show my permit because the authorizing signature on the permit are their names. And this is part of the proof that I have physical evidence that I've been asked not to share." Ron also says that "It's their opinion, should the Israeli people, as a whole, learn that the Ark of the Covenant has been found, that they would want to build a temple to house it in." In this interview Ron also states—prophesizes—that in due time the truth of the Ark of the Covenant, the Ten Commandment tablets, and the blood of Jesus Christ will be revealed to the whole world, and this will conclude the spreading of the Gospel to the world, and then the End will come. You’re watching this video. Is this time now? Here’s some background information on the institution that has taken part in the conspiracy to hide the blood of Jesus and the results of the analysis of His blood DNA—and the corrupt conspirators that work for it. The Israel Antiquities Authority (IAA‎, before 1990, the Israel Department of Antiquities) is an independent Israeli governmental authority responsible for enforcing the 1978 Law of Antiquities. The IAA regulates excavation and conservation, and promotes research. The director-general is Shuka Dorfmann and its offices are housed in the Rockefeller Museum. Gen. Amir Drori – Upon his retirement from the IDF he was appointed head of the Israeli Ministry of Education's Department of Antiquities. Under his guidance and leadership the department was expanded and restructured, in 1990 becoming the Israel Antiquities Authority (IAA) with Drori as its first director general. Dan Bahat – Dan Bahat is one of Israel's leading archaeologists and a senior lecturer at the Land of Israel Studies at Bar-Ilan University. He is an expert on the Temple Mount, Herod's Palace, and the 1,600-foot tunnel that runs under the western retaining wall of the Temple Mount. Yosef Gat – Directed Talpiot Tomb excavations for the Israeli Department of Antiquities Amos Kloner – Archaeologist and professor emeritus in the Martin Szusz Department of the Land of Israel Studies at the Bar Ilan University in Ramat Gan, Israel, where he teaches Hellenistic, Roman, and Byzantine archaeology. So, the bottom line—and the big picture—is this: the Illuminati bloodline Rockefeller family is working on behalf of Satan and his New World Order to supress the truth. Will you believe Satan's ambassadors for America, or a righteous man of truth and God—who, despite the efforts of Israeli authorities and MOSSAD, still has evidence to prove that there was a cover-up? 📌 A team of research scientists working for a private facility in Tel Aviv did a genetic analysis from a blood sample widely believed to belong to Jesus, concluding that Jesus’ biological mother was a normal human female, while His father was “not a human male” (Jesus apparently has DNA twice as sophisticated as a normal human being’s). The Astonishing DNA Analysis of Jesus Christ https://youtu.be/Fu6eLDmAkwE Proof That Ron Wyatt Was Telling the Truth https://youtu.be/lXqdaejBRSE Jesus’ DNA Discoverer’s DEATH BED CONFESSION https://youtu.be/rBb8iaV5FPE 4 Places Jesus' Blood Was Found https://youtu.be/et_-FEGHW20 God Said Jesus is His Son (So Does Jesus' DNA) https://youtu.be/9wDy0x31Vzc Please Subscribe→https://www.youtube.com/subscription_center?add_user=whiteknightnews #Jesus #BloodOfJesus #JesusDNA #CoverUp #conspiracy #NewWorldOrder #NWO #Illuminati
Views: 9986 White Knight News
In vitro Chromosomal Aberration - OECD 473
 
17:23
Regulatory requirements for in vitro genotoxicity testing vary by industry. In this video, we discuss how chromosomal aberration fits in to mutagenicity testing strategies.
Views: 1788 Cyprotex Discovery
Genetic analyses for accurate diagnosis of blood cancer (Ann Lab Med)
 
03:04
Timely diagnosis and intervention is critical for patients with blood cancer and recent advances in genetics have considerably improved diagnostics. Know more about a Korean study that analyzed mutations in calreticulin or CALR gene for diagnosing myeloproliferative neoplasms For more details, read the full paper in Annals of Laboratory Medicine http://dx.doi.org/10.3343/alm.2015.35.1.22 published by the Korean Society for Laboratory Medicine (KSLM)
Aga Khan Lab Test Charges
 
02:01
Aga Khan Lab Test Charges Join Our Youtube Channel http://www.youtube.com/user/awamiwebcom Follow us on Twitter https://twitter.com/awamiweb Follow us on Google+ https://plus.google.com/106110190206490570499/ Like us on Facebook https://Facebook.com/AwamiWeb/
Views: 26566 Awami Web
Breaking Leukemia's Limits of Detection with Droplet Digital™ PCR
 
10:29
For more info, visit http://www.bio-rad.com/droplet. Prof. Alec Morley, a pioneer in digital PCR, describes his use of Droplet Digital PCR (ddPCR™) technology to advance the diagnosis and treatment of leukemia. Morley and his colleagues at Flinders University and Medical Center in Adelaide, South Australia previously developed a digital PCR method for the early detection of residual acute lymphoblastic leukemia (ALL) using a genetic marker instead of traditional microscopy of bone marrow cells, enabling more accurate prediction of relapse risk for ALL patients following chemotherapy. Monoquant, a company founded by Morley to commercialize the research in his lab, has now chosen Bio-Rad's ddPCR System to develop a new clinical test for chronic myeloid leukemia (CML). The unparalleled sensitivity of ddPCR technology promises great improvement over conventional qPCR tests and also eliminates the variability in amplification efficiency that results from using patient-specific PCR primers, removing a potential roadblock to FDA approval. The QX200™ Droplet Digital PCR System, Bio-Rad's second-generation digital PCR system, provides absolute quantification of target DNA or RNA molecules using EvaGreen or TaqMan hydrolysis probes, yielding unmatched sensitivity and precision for a wide variety of applications.
Views: 1467 Bio-Rad Laboratories
Fanconi Anemia : Symptoms, Diagnosis, Treatment | Know How to Diagnose Fanconi Anemia
 
05:56
====================================================== SUBSCRIBE TO MY CHANNEL PLEASE.... https://www.youtube.com/channel/UCWDyU5Z3SKdlZ0tL8WLsvRw?sub_confirmation=1 ===================================================== How to Diagnose Fanconi Anemia. How Is Fanconi Anemia Diagnosed? | How Is Fanconi Anemia Diagnosed? | Fanconi Anemia Workup: Approach Considerations, CBC Count | Fanconi Anemia: Causes, Symptoms and Diagnosis - Healthline | Fanconi Anemia - NORD (National Organization for Rare Disorders) | Diagnosis of Fanconi Anemia: Chromosomal Breakage Analysis | Diagnosis of Fanconi Anemia By Chromosome Breakage Tests | People also ask What are the signs and symptoms of Fanconi anemia? How do you get Fanconi anemia? Can you cure Fanconi anemia? What is the meaning of Fanconi anemia? Keywords: #fanconi anemia genetic testing #fanconi anemia pictures #treatment of fanconi anemia #chromosome breakage test #fanconi anemia causes #fanconi anemia definition #fanconi anemia pathophysiology #fanconi anemia life expectancy ------------------------------------------------------------------------------------------------------- THANKS FOR WATCHING OUR CHANNEL -------------------------------------------------------------------------------------------------------- -~-~~-~~~-~~-~- Please watch: "🍳🍳⛹Child's Anemia Know How to Deal with Your Child's Anemia" https://www.youtube.com/watch?v=7CVvsGLuXoE -~-~~-~~~-~~-~-
Views: 1050 how to easily
AMP 2015 - Many Tests, One Report: Integrating NGS with FISH & Cytogenetics for Clinical Application
 
56:54
GenomOncology's 2015 AMP Corporate Workshop on Wednesday, November 4, 2015 Speakers: Dr. Stephen C. Peiper Professor and Chairman of the Department of Pathology, Anatomy and Cell Biology at Thomas Jefferson University Dr. Mia A. Levy Co-Founder of My Cancer Genome Director of Cancer Clinical Informatics for the Vanderbilt-Ingram Cancer Center Historically, labs have reported on FISH, karyotyping, and NGS results for a patient separately, leaving oncologists without interpretation of the collective impact of individual results. Dr. Peiper describes providing comprehensive interpretation of these test results in a single report. Dr. Levy presents My Cancer Genome’s approach to curating content that supports interpretation of multiple test modes across hundreds of genes.
Views: 307 GenomOncology
What is FEMALE SPERM? What does FEMALE SPERM mean? FEMALE SPERM meaning & explanation
 
05:10
What is FEMALE SPERM? What does FEMALE SPERM mean? FEMALE SPERM meaning - FEMALE SPERM definition - FEMALE SPERM explanation. SUBSCRIBE to our Google Earth flights channel - https://www.youtube.com/channel/UC6UuCPh7GrXznZi0Hz2YQnQ Source: Wikipedia.org article, adapted under https://creativecommons.org/licenses/by-sa/3.0/ license. Female sperm can be either: 1. A sperm that contains an X chromosome, produced in the usual way by a male, referring to the occurrence of such a sperm fertilizing an egg and giving birth to a female. 2. Sperm containing genetic material from a female. We'll focus on 2nd definition in this video. Since the late 1980s, scientists have explored how to produce sperm where all of the chromosomes come from a female donor. In the late 1990s, this concept became a partial reality when scientists in Japan developed chicken female sperm by injecting bone marrow stem cells from a female chicken into a rooster's testicles. This technique proved to fall below expectations, however, and has not yet been successfully adapted for use on humans. Creating female sperm was first raised as a possibility in a patent filed in 1991 by injecting a woman's cells into a man's testicles, though the patent focused mostly on injecting altered male cells into a man's testes (to correct genetic diseases). In 1997, Japanese scientists partially confirmed such techniques by creating chicken female sperm in a similar manner. "However, the ratio of produced W chromosome-bearing (W-bearing) spermatozoa fell substantially below expectations. It is therefore concluded that most of the W-bearing PGC could not differentiate into spermatozoa because of restricted spermatogenesis." These simple transplantation methods follow from earlier observations by developmental biologists that germ stem cells are autonomous in the sense that they can begin the processes to become both sperm and eggs. One potential roadblock to injecting a woman's cells into a man's testicles is that the man's immune system might attack and destroy the woman's cells. In usual circumstances, when foreign cells (such as cells or organs from other people, or infectious bacteria) are put into a human body, its immune system will reject such cells or organs. However, a special property of a man's testicles is that they are immune-privileged, that is, a man's immune system will not attack foreign cells (such as a woman's cells) injected into the sperm-producing part of the testicles. Thus, a woman's cells will remain in the man's testicles long enough to be converted into sperm. However, there are more serious roadblocks. Biologists have well established that male sperm production relies on certain genes on the Y chromosome, which, when missing or defective, lead to such men producing little to no sperm in their testicles. An analogy, then, is that a cell from a woman has complete Y chromosome deficiency. While many genes on the Y chromosome have backups (homologues) on other chromosomes, a few genes such as RBMY on the Y chromosome do not have such backups, and their effects must be compensated for to convert cells from a woman into sperm. In 2007, a patent application was filed on methods for creating human female sperm using artificial or natural Y chromosomes and testicular transplantation. Key to successful creation of female sperm (and male eggs) will be inducing male epigenetic markings for female cells that initially have female markings, with techniques for doing so disclosed in the patent application. Scientists from the University of Newcastle upon Tyne led by biologist Karim Nayernia discovered a method of creating partly developed sperm cells, otherwise known as "spermatogonial" stem cells, from the bone marrow of male volunteers, entirely in-vitro (outside the human body), and is seeking funding to see whether such techniques can be used to make female sperm. If created, a "female sperm" cell could fertilize an egg cell, a procedure that, among other potential applications, might enable female same-sex couples to produce a child that would be the biological offspring of its two mothers. It is also claimed that production of female sperm may stimulate a female to be both the mother and father (similar to asexual reproduction) of an offspring produced by her own sperm. Many queries, both ethical and moral, arise over these arguments.
Views: 1644 The Audiopedia
What Is The Definition Of AML Medical Dictionary Free Online
 
03:04
what is the definition of AML: Acute myeloid leukemia (also known as acute myelogenous leukemia), a quickly progressive malignant disease in which there are too many immature blood-forming cells in the blood and bone marrow, the cells being specifically those destined to give rise to the granulocytes or monocytes, both types of white blood cells that fight infections. In AML, these blasts do not mature and so become too numerous. AML can occur in adults or children. Acute myeloid leukemia is also known as acute myelogenous leukemia or acute nonlymphocytic leukemia (ANLL). The early signs of AML may be similar to the flu or other common diseases with fever, weakness and fatigue, loss of weight and appetite, and aches and pains in the bones or joints. Other signs of AML may include tiny red spots in the skin, easy bruising and bleeding, frequent minor infections, and poor healing of minor cuts. First, blood tests are done to count the number of each of the different kinds of blood cells and see whether they are within normal ranges. In AML, the red blood cell levels may be low, causing anemia; platelet levels may be low, causing bleeding and bruising; and the white blood cell levels may be low, leading to infections. A bone marrow biopsy or a bone marrow aspiration may be done if the results of the blood tests are abnormal. During a bone marrow biopsy, a hollow needle is inserted into the hip bone to remove a small amount of the marrow and bone for examination under a microscope. In a bone marrow aspirate, a small sample of liquid bone marrow is withdrawn through a syringe. A lumbar puncture, or spinal tap, may be done to see if the disease has spread into the cerebrospinal fluid, which surrounds the central nervous system (CNS) -- the brain and spinal cord. Other key diagnostic tests may include flow cytometry (in which cells are passed through a laser beam for analysis), immunohistochemistry (using antibodies to distinguish between types of cancer cells), cytogenetics (to determine chromosome changes in cells), and molecular genetic studies (DNA and RNA tests of the cancer cells). The primary treatment of AML is chemotherapy. Radiation therapy is less common; it may be used in certain cases. Bone marrow transplantation is under study in clinical trials and is coming into increasing use. There are two phases of treatment for AML. The first phase is called induction therapy. The purpose of induction therapy is to kill as many of the leukemia cells as possible and induce a remission, a state in which there is no visible evidence of disease and blood counts are normal. Patients may receive a combination of drugs during this phase including daunorubicin, idarubicin, or mitoxantrone plus cytarabine and thioguanine. Once in remission with no signs of leukemia, patients enter a second phase of treatment. The second phase of treatment is called post-remission therapy (or continuation therapy). It is designed to kill any remaining leukemic cells. In post-remission therapy, patients may receive high doses of chemotherapy, designed to eliminate any remaining leukemic cells. Treatment may include a combination of cytarabine, daunorubicin, idarubicin, etoposide, cyclophosphamide, mitoxantrone, or cytarabine. There are a number of different subtypes of AML. AML is classified using a system called the French American British (FAB) system. In the this system, the subtypes of AML are grouped according to the particular cell line in which the disease developed. There are eight distinct types of AML, designated M0 through M7. Types M2 (myeloblastic leukemia with maturation) and M4 (myelomonocytic leukemia) each account for 25% of AML; M1 (myeloblastic leukemia, with few or no mature cells) accounts for 15%; M3 (promyelocytic leukemia) and M5 (monocytic leukemia) each account for 10% of cases; the other subtypes are rarely seen. AML is also classified according to the chromosomal abnormalities in the malignant cells. medical terminology, medical dictionary, medical dictionary free download, medical terminology made easy, medical terminology song
Stem Cell Therapy for Leukemia
 
07:23
Full Lesson Here: http://ed.ted.com/on/g7P19NfN Dubay points out that stem cell therapy dates back to the 1950's and highlights some landmark discoveries in the treatment of leukemia from HLA matching to the use of cord blood.
Views: 1740 Dan Dubay
Dr. Pamela Crilley on Prescribing TKIs for the Treatment of CML
 
01:16
Pamela Crilley, DO, medical oncologist, Cancer Treatment Centers of America, Eastern Regional Medical Center, explains the benefits and downfalls of prescribing TKIs for the treatment of CML. While a TKI is less invasive than a bone marrow transplant, the toxicity of TKIs remains a factor, especially considering the length of time a patient must be treated. Research is being conducted to analyze the outcome of CML patients based on the rapidity of which they reach milestones. For more resources visit: http://targetedhc.com/
Views: 168 Targeted Oncology
Making Sense of Tetrad
 
02:23
Tetrad tests are a type of discrimination test used to determine if a noticeable difference exists between two samples. Learn how sensory professionals use Tetrad tests to help them make important decisions about their products.
Views: 1203 Compusense Inc
Stem Cell Gene Therapy
 
09:52
In this video a group of students explain a self-taught and self-researched lesson, through visual understanding and analysis. It explains and shows how "Stem Cell Gene Therapy" can potentially change the upcoming generations. This type of gene therapy can exponentially decrease the amounts of deaths happening in this world, caused by Cancerous Disease, Alzheimer's, Parkinson, and so on. This in a high school project which was submitted and presented in class. We do not take any intended rights for these background images and or effects, please do understand. If by any means, us using your produced music or footage frustrates you or makes you unpleasant, please contact us and we will immediately remove it, we respect and love any of your work which was presented in this video, Thank You A Huge Thanks To : 1) Holt mcdougal biology textbook 2) Google dictionary 3) Vogt-James, Mirabai. “UCLA Stem Cell Researchers Develop Promising Method to Treat Sickle Cell Disease.” UCLA Newsroom, 4 Mar. 2015, newsroom.ucla.edu/releases/ucla-stem-cell-researchers-develop-promising-method-to-treat-sickle-cell-disease. (image only) 4) CIRMTV. “Defeating Sickle Cell Disease with Stem Cells Gene Therapy: Stem Cells in Your Face, Episode 2.” YouTube, YouTube, 6 May 2015, www.youtube.com/watch?v=f3pjyQvBdz0. 5) “Stem Cell Basics I.” National Institutes of Health, U.S. Department of Health and Human Services, stemcells.nih.gov/info/basics/1.htm. 6) “Gene Therapy Explained.” YouTube, YouTube, 28 Nov. 2016, www.youtube.com/watch?v=xOQFJJOBGM0. 7) lifenoggin. “WHAT CAN STEM CELLS DO?” YouTube, YouTube, 27 Apr. 2015, www.youtube.com/watch?v=K7D6iA7bZG0.
Views: 229 1948Ismael
How aneuploidy drives cancer
 
01:03:28
How aneuploidy drives cancer Air date: Wednesday, May 24, 2017, 3:00:00 PM Category: WALS - Wednesday Afternoon Lectures Runtime: 01:03:27 Description: NIH Director's Wednesday Afternoon Lecture Series Aneuploidy has been recognized as a hallmark of cancer for more than 100 years, yet no general theory has emerged to explain the recurring patterns of aneuploidy in cancer. Dr. Elledge's laboratory developed the Tumor Suppressor and Oncogene (TUSON) Explorer, a computational method that analyzes the patterns of mutational signatures in tumors and predicts the likelihood that any individual gene functions as a tumor suppressor gene (TSG) or an oncogene (OG). By analyzing more than 8,200 tumor-normal pairs, his lab has provided statistical evidence suggesting that many more genes possess cancer-driver properties than anticipated, forming a continuum of oncogenic potential. These genes represent the vast majority of cancer drivers, and the genetic networks they drive are a focus of future cancer system-biological approaches to cancer research. By integrating the driver predictions with information on somatic copy-number alterations, his lab has found that the distribution and the potency of TSGs (STOP genes), OGs, and essential genes (GO genes) on chromosomes can predict the complex patterns of aneuploidy and copy-number variation characteristic of cancer genomes. The lab proposes that the cancer genome is shaped through a process of cumulative haploinsufficiency and triplosensitivity. Dr. Elledge and his lab are now assessing how aneuploidy drives cancer and the potency with which it does so. They have found that, in many cases, aneuploidy predicts survival better than do mutational drivers or existing clinical parameters. They have also discovered that different classes of aneuploidy drive transcriptional programs for two hallmarks of cancer. Aneuploidy promotes a cell-proliferation program and inhibits the infiltration of immune cells leading to immune evasion. Melanoma patients with tumors exhibiting high aneuploidy show poorer responses to immunotherapy with anti-CTLA4 antibodies. Dr. Elledge and his lab are now exploring which genes in recurring amplicons drive proliferation. For more information go to https://oir.nih.gov/wals/2016-2017 Author: Stephen J. Elledge, Ph.D., Gregor Mendel Professor of Genetics and Medicine at Harvard Medical School; Geneticist, Department of Medicine, Brigham and Women's Hospital; Investigator, Howard Hughes Medical Institute Permanent link: https://videocast.nih.gov/launch.asp?23313
Views: 753 nihvcast
Du145 cancer cells
 
00:31
Du145 cells are from the prostate carcinoma cell lines taken from the brain metastasis. (This is me spending wayyyy too much time at work: Ottawa Regional Cancer Center, Ottawa Hospital)
Views: 10550 jzkhan1978

What is a cover letter for a resume definition
Example of a great cover letter for resume
Custom essays writing service
Job cover letter opening greeting
Termios sample cover letter